Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

KRA-533

😃Good
Catalog No. T38411Cas No. 10161-87-2

KRA-533, a potent KRAS agonist, directly targets the GTP/GDP binding pocket within the KRAS protein, inhibiting GTP cleavage. This inhibition leads to the buildup of constitutively active GTP-bound KRAS, which subsequently activates both apoptotic and autophagic cell death pathways specifically in cancer cells.

KRA-533

KRA-533

😃Good
Catalog No. T38411Cas No. 10161-87-2
KRA-533, a potent KRAS agonist, directly targets the GTP/GDP binding pocket within the KRAS protein, inhibiting GTP cleavage. This inhibition leads to the buildup of constitutively active GTP-bound KRAS, which subsequently activates both apoptotic and autophagic cell death pathways specifically in cancer cells.
Pack SizePriceAvailabilityQuantity
2 mg$1345 days
Bulk & Custom
Add to Cart
Questions
View More
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
KRA-533, a potent KRAS agonist, directly targets the GTP/GDP binding pocket within the KRAS protein, inhibiting GTP cleavage. This inhibition leads to the buildup of constitutively active GTP-bound KRAS, which subsequently activates both apoptotic and autophagic cell death pathways specifically in cancer cells.
In vitro
KRA-533, at a concentration of 10 μM and after 48 hours of treatment, significantly increases KRAS activity in HCC827 cells. In H157 cells, a dosage range of 0 to 15 μM over 48 hours elevates KRAS activity proportionally, correlating with higher levels of pERK, an increased ratio of active caspase 3 to procaspase 3, and PARP cleavage, culminating in apoptosis. Furthermore, a 10-day exposure of H292 cells to 10 μM of KRA-533 suppresses cell growth, especially in cells with KRAS mutations. KRA-533 also demonstrates the ability to bind directly to wild-type and G12C, G12D, and G13D mutant KRAS proteins, activating wild-type KRAS and intensifying the activity of mutant KRAS in a dose-responsive manner. Western Blot analysis on HCC827 cells and apoptosis analysis on H157 cells, both conducted at varying concentrations and durations, confirm the compound's dual effects of enhancing KRAS activity and inducing apoptotic cell death.
In vivo
KRA-533, administered intraperitoneally (I.p.) at dosages ranging from 0 to 30 mg/kg over 28 days, exhibits dose-dependent suppression of tumor growth in lung cancer mutant KRAS xenografts in Nu/Nu nude mice. It also induces apoptosis and autophagy within tumor tissues in a similar dose-dependent fashion. The therapeutic efficacy of KRA-533 is determined to be optimal at dosages between 7.5 mg/kg and 30 mg/kg.
Chemical Properties
Molecular Weight314.179
FormulaC13H16BrNO3
Cas No.10161-87-2
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy KRA-533 | purchase KRA-533 | KRA-533 cost | order KRA-533 | KRA-533 chemical structure | KRA-533 in vivo | KRA-533 in vitro | KRA-533 formula | KRA-533 molecular weight